Cyclin-dependent kinase

Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Monday, November 21, 2022
The Monarch School, Adult, Cell death, Food and Drug Administration, PI3K, Growth, Cancer, EMBER, Cyclin D1, Recurrence, Plasma, Breast, Febrile neutropenia, PIK3CA, Rb, Woman, Cell proliferation, Diarrhea, SERD, Infection, ER, Tamoxifen, Traffic barrier, CDK, Physician, Cerebrospinal fluid, Eli Lilly and Company, FDA, Breast cancer, Breast cancer classification, Phosphorylation, ESR1, ET, EBC, NYSE, OS, S phase, Hospital, Pharmacology, Patient, Molecular biology, Grade 3, Apoptosis, Toxicity, Risk, Dehydration, Cyclin-dependent kinase, Loperamide, Lilly, Retinoblastoma protein, Food, Cell cycle, Preclinical development, Grade 2, Pharmaceutical industry, Birth control, Medical imaging, Abemaciclib, Neutropenia, G1

INDIANAPOLIS, Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held December 6-10, 2022, in San Antonio, Texas, and virtually.

Key Points: 
  • INDIANAPOLIS, Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held December 6-10, 2022, in San Antonio, Texas, and virtually.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.
  • In patients with advanced cancer, including breast cancer, concentrations of Verzenio and its active metabolites (M2 and M20) in cerebrospinal fluid are comparable to unbound plasma concentrations.

Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022

Retrieved on: 
Wednesday, October 26, 2022
Company, National University Hospital, MYC, Endometrial cancer, City of Hope National Medical Center, Safety, Cyclin E, CTD, Lymphatic system, Hematology, RNAP, HER2, CDK, CR, Cyclin, Risk, BCL2, CLL, Trastuzumab, Breast cancer, Uterine serous carcinoma, Cyclin-dependent kinase, CDK9, RNA, Annual report, Phosphorylation, Patient, Multiple myeloma, NCT, MCL1, CCNE, ALL, News, Adult, Research, COVID-19, Lymphoma, PLK1, FDA, B-cell lymphoma, RNA polymerase II, CDK2, AML, Ovarian cancer, All rights reserved, Cell cycle, Gene, Neuroblastoma, MD Anderson Cancer Center, Cyclacel, Pharmaceutical industry

Fadraciclib, a next generation CDK inhibitor, is a highly selective, potent, orally and intravenously available, inhibitor of CDK2 and CDK9.

Key Points: 
  • Fadraciclib, a next generation CDK inhibitor, is a highly selective, potent, orally and intravenously available, inhibitor of CDK2 and CDK9.
  • By inhibiting CDK2 and CDK9 fadraciclib causes apoptotic death of cancer cells at sub-micromolar concentrations.
  • Fadraciclib is being tested in a Phase 1/2 trial for the treatment of advanced solid tumors and lymphoma (065-101; NCT#04983810 ) and a Phase 1/2 trial for the treatment of hematological malignancies (065-102; NCT#05168904 ).
  • In a prior Phase 1 open-label trial (CYC065-01), patients with high copy CCNE (cyclin E), MYC or MCL1 showed sensitivity to intravenously administered, single-agent fadraciclib.

Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium

Retrieved on: 
Thursday, October 13, 2022
Cyclin E, News, RNAP, PLK1, Risk, CLL, All rights reserved, AML, Lymphoma, Multiple myeloma, Annual report, Patient, Neuroblastoma, Cyclacel, Research, RNA, CDK2, CR, B-cell lymphoma, HER2, Endometrial cancer, RNA polymerase II, Cyclin-dependent kinase, Company, Trastuzumab, Phosphorylation, CCNE, Breast cancer, Uterine serous carcinoma, Adult, Safety, MYC, BCL2, CDK9, Lymphatic system, Hematology, Cell cycle, ALL, FDA, COVID-19, CDK, NCT, MCL1, Gene, Ovarian cancer, CTD, Pharmaceutical industry

Fadraciclib, a next generation CDK inhibitor, is a highly selective, potent, orally and intravenously available, inhibitor of CDK2 and CDK9.

Key Points: 
  • Fadraciclib, a next generation CDK inhibitor, is a highly selective, potent, orally and intravenously available, inhibitor of CDK2 and CDK9.
  • Fadraciclib is being tested in a Phase 1/2 trial for the treatment of advanced solid tumors and lymphoma (065-101; NCT#04983810 ) and a Phase 1/2 trial for the treatment of hematological malignancies (065-102; NCT#05168904 ).
  • In a prior Phase 1 open-label trial (CYC065-01), patients with high copy CCNE (cyclin E), MYC or MCL1 showed sensitivity to intravenously administered, single-agent fadraciclib.
  • The Cyclacel logo and Cyclacel are trademarks of Cyclacel Pharmaceuticals, Inc.

Lilly Announces Details of Presentations at ESMO Congress 2022

Retrieved on: 
Wednesday, September 7, 2022
Patient, Breast cancer, Cyclin D1, Cell cycle, Technology, Food and Drug Administration, Preclinical development, S phase, Man, Recurrence, RET, Rb, EBC, Food, Transfection, CDK, Traffic barrier, Lilly, Tamoxifen, Plasma, FDA, Phosphorylation, Breast cancer classification, Adult, ET, Cell death, Cell proliferation, Cerebrospinal fluid, Woman, Growth, Apoptosis, Cyclin-dependent kinase, Retinoblastoma protein, Pharmaceutical industry, Medical imaging, Abemaciclib, G1

A Grade 3 decrease in neutrophil count (based on laboratory findings) occurred in 19 to 32% of patients receiving Verzenio.

Key Points: 
  • A Grade 3 decrease in neutrophil count (based on laboratory findings) occurred in 19 to 32% of patients receiving Verzenio.
  • Lilly unites caring with discovery to create medicines that make life better for people around the world.
  • P-LLY
    Verzenio and Retevmo are trademarks owned by or licensed toEli Lilly and Company, its subsidiaries, or affiliates.
  • Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
Rb, Cell proliferation, Lilly, Cyclin D1, Traffic barrier, Breast cancer, Cyclin-dependent kinase, HR, Patient, Woman, Cell death, Adult, Preclinical imaging, FDA, Retinoblastoma protein, Recurrence, U.S. FDA, S phase, Cerebrospinal fluid, Plasma, CDK, Man, Technology, RET, Apoptosis, Phosphorylation, Breast cancer classification, Transfection, Growth, Cell cycle, EBC, Pharmaceutical industry, Medical imaging, G1, Abemaciclib

Imlunestrant was specifically designed to deliver continuous estrogen receptor target inhibition throughout the dosing period and regardless of ESR1 mutational status.

Key Points: 
  • Imlunestrant was specifically designed to deliver continuous estrogen receptor target inhibition throughout the dosing period and regardless of ESR1 mutational status.
  • Interested patients and physicians can contact the Loxo Oncology at Lilly clinical trial team by e-mailing [email protected] .
  • Across four clinical trials in 3691 patients, diarrhea occurred in 81 to 90% of patients who received Verzenio.
  • Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

CDK Global to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on August 17, 2021

Retrieved on: 
Thursday, July 15, 2021
CDK Global, Cell Cycle, Companies, CDK, NASDAQ, Cyclin-dependent kinase, Finance

HOFFMAN ESTATES, Ill., July 15, 2021 (GLOBE NEWSWIRE) -- CDK Global, Inc. (Nasdaq: CDK), a leading retail automotive technology company, is scheduled to release its financial results for the fiscal fourth quarter and year ended June 30, 2021 after the closing of the Nasdaq market on Tuesday, August 17, 2021.

Key Points: 
  • HOFFMAN ESTATES, Ill., July 15, 2021 (GLOBE NEWSWIRE) -- CDK Global, Inc. (Nasdaq: CDK), a leading retail automotive technology company, is scheduled to release its financial results for the fiscal fourth quarter and year ended June 30, 2021 after the closing of the Nasdaq market on Tuesday, August 17, 2021.
  • CDK will also be hosting a conference call at 4:00 p.m. CT on August 17, 2021 to discuss the results for the period.
  • A supplemental slide presentation will be available approximately 30 minutes before the webcast on the CDK Investor Relations home page.
  • CDK Global (Nasdaq: CDK) is a leading provider of integrated data and technology solutions to the automotive, heavy truck, recreation, and heavy equipment industries.

Carketa, Inc. Joins CDK Global Partner Program

Retrieved on: 
Monday, July 12, 2021
Computing, Cell Cycle, CDK, Cyclin-dependent kinase, Software, Companies

"We're very pleased to introduce Carketa as the newest member of the CDK Global Partner Program," said Howard Gardner, vice president and general manager, CDK Data Services. "

Key Points: 
  • "We're very pleased to introduce Carketa as the newest member of the CDK Global Partner Program," said Howard Gardner, vice president and general manager, CDK Data Services. "
  • The CDK Global Partner Program provides its partners with access to a diverse CDK ecosystem through the ability to integrate with a range of CDK applications, as well as with CDK dealer websites.
  • The CDK Partner Program now numbers more than 430 partner companies and 600 unique applications auto dealers can use to run their businesses.
  • As part of the CDK ecosystem, the CDK Partner Program provides data and workflow integration to a wide range of third parties, OEMs and dealers.

CDK Global Introduces CDK OnePay Fueled by Global Payments

Retrieved on: 
Tuesday, June 15, 2021
Data management, General Automotive, Technology, Retail, Other Automotive, Tires & Rubber, Recreational vehicles, Performance & Special Interest, Off-Road Trucks & SUVs, Alternative Vehicles, Fuels, Motorcycles, Fleet management, Banking, Professional services, Trucking, Aftermarket, Online Retail, Automotive, Transport, Other Technology, Software, Hardware, CDK Global, CDK, Cyclin-dependent kinase

CDK Global, Inc. (Nasdaq: CDK), a leading retail automotive technology company, today launched CDK OnePay , a dealership-wide payment solution fueled by Global Payments , a leading worldwide provider of payment technology and software solutions.

Key Points: 
  • CDK Global, Inc. (Nasdaq: CDK), a leading retail automotive technology company, today launched CDK OnePay , a dealership-wide payment solution fueled by Global Payments , a leading worldwide provider of payment technology and software solutions.
  • CDK OnePay is another example of how were driving innovation of the tools dealers use every day to improve efficiency and profitability in their operations, said Joe Tautges, chief operating officer, CDK Global.
  • CDK OnePay is offered to dealers with no upfront or recurring subscription fees from CDK.
  • Technology has transformed payments in recent years, but many industry sectors are still catching up, said Bob Cortopassi, president, Global Payments Integrated.

Weave Workforce Joins CDK Global Partner Program

Retrieved on: 
Monday, May 17, 2021
Cell Cycle, Computing, CDK Global, CDK, Cyclin-dependent kinase, Weave, Software, Technology

b'ANN ARBOR, Mich., May 17, 2021 /PRNewswire-PRWeb/ -- Weave Workforce , a labor optimization company providing AI-based forecasting and employee scheduling, today announced that it has become a participant in the CDK Global Partner Program .

Key Points: 
  • b'ANN ARBOR, Mich., May 17, 2021 /PRNewswire-PRWeb/ -- Weave Workforce , a labor optimization company providing AI-based forecasting and employee scheduling, today announced that it has become a participant in the CDK Global Partner Program .
  • As a member of one of the largest third-party partner programs in the industry, Weave Workforce is now part of a marketplace of applications and integration that CDK Global, Inc. (Nasdaq: CDK), a leading enabler of end-to-end automotive commerce, developed to help automotive dealers succeed.\n"We are honored and excited to join such an extensive network," says Weave Workforce CEO John Larsen.
  • Taking into consideration each dealership\'s unique business parameters, AI-powered Weave Workforce software maximizes proficiency by increasing productivity and efficiency on the shop floor.\n"We\'re very pleased to introduce Weave Workforce as the newest member of the CDK Global Partner Program," said Howard Gardner, vice president and general manager, CDK Data Services.
  • "\nThe CDK Global Partner Program provides its partners with access to a diverse CDK ecosystem through the ability to integrate with a range of CDK applications, as well as with CDK dealer websites.\nThe CDK Partner Program now numbers more than 430 partner companies and 600 unique applications auto dealers can use to run their businesses.

CME Outfitters Accepts 2020 Award for Best Practice in CME Outside of the USA

Retrieved on: 
Wednesday, April 14, 2021
Medical education, Continuing medical education, Branches of biology, Breast cancer, CME, Metastatic breast cancer, Cyclin-dependent kinase, Biology, Health

b'BETHESDA, Md., April 14, 2021 /PRNewswire-PRWeb/ -- CME Outfitters (CMEO), a leading accredited provider of continuing medical education and a division of NexPhase Capital-backed KnowFully Learning Group, was presented with the National Association of Medical Education Companies\' (NAMEC) 2020 Award for Best Practice in CME Outside of the USA this Spring.

Key Points: 
  • b'BETHESDA, Md., April 14, 2021 /PRNewswire-PRWeb/ -- CME Outfitters (CMEO), a leading accredited provider of continuing medical education and a division of NexPhase Capital-backed KnowFully Learning Group, was presented with the National Association of Medical Education Companies\' (NAMEC) 2020 Award for Best Practice in CME Outside of the USA this Spring.
  • The NAMEC Best Practice in CME Awards recognize best practices, ideas or processes that can be implemented by NAMEC members to improve CME.\nThis award was given in recognition of CMEO\'s submission entitled, Real-World Evidence: CDK 4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer.
  • "In these short-form online activities, learners are able to gain valuable insights on key topics they can immediately apply to their practice.
  • "\n"This award is appreciated and demonstrates CMEO\'s growing compendium of activities in oncology and our focus on growth outside of the United States.